Park and colleagues reported in an interim analysis from a prospective phase II trial that prophylactic anakinra resulted in a low incidence of ICANS in patients with R/R lymphoma treated with CD19-targeting CAR T-cells [64]. The gene discussed is CD19; the disease is lymphoma.